Publication:
Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020-2022: In-silico Whole-Genome Sequence Analysis

dc.contributor.authorMekonnen, Daniel
dc.contributor.authorMunshea, Abaineh
dc.contributor.authorNibret, Endalkachew
dc.contributor.authorAdnew, Bethlehem
dc.contributor.authorGetachew, Hailu
dc.contributor.authorKebede, Amiro
dc.contributor.authorGebrewahid, Ananya
dc.contributor.authorHerrera-León, Silvia
dc.contributor.authorAramendia, Aranzazu Amor
dc.contributor.authorBenito, Agustin
dc.contributor.authorAbascal, Estefanía
dc.contributor.authorJacqueline Forget, Camille
dc.contributor.authorAseffa, Abraham
dc.contributor.authorHerrera-Leon, Laura
dc.contributor.funderBahir Dar University (Etiopía)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderInternational Federation of Clinical Chemistry and Laboratory Medicine (IFCC)es_ES
dc.date.accessioned2023-11-14T12:44:18Z
dc.date.available2023-11-14T12:44:18Z
dc.date.issued2023-10
dc.description.abstractIntroduction: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible for most drug resistance in Ethiopia are not well described. Hence, this study aimed to identify the leading drug resistance sub-lineages and characterize first-line anti-tuberculosis drug resistance-associated single nucleotide polymorphisms (SNPs). Methods: A facility-based cross-sectional study was conducted in 2020-2022 among new and presumptive multidrug resistant-TB (MDR-TB) cases in Northwest Ethiopia. Whole-genome sequencing (WGS) was performed on 161 isolates using Illumina NovaSeq 6000 technology. The SNP mutations associated with drug resistance were identified using MtbSeq and TB profiler Bioinformatics softwares. Results: Of the 146 Mtb isolates that were successfully genotyped, 20 (13.7%) harbored one or more resistance-associated SNPs. L4.2.2.ETH was the leading drug-resistant sub-lineage, accounting for 10/20 (50%) of the resistant Mtb. MDR-TB isolates showed extensive mutations against first-line anti-TB drugs. Ser450Leu/(tcg/tTg) for Rifampicin (RIF), Ser315Thr/(agc/aCc) for Isoniazid (INH), Met306Ile/(atg/atA(C)) for Ethambutol (EMB), and Gly69Asp for Streptomycin (STR) were the leading resistance associated mutations which accounted for 56.5%, 89.5%, 47%, and 29.4%, respectively. The presence of both clustered and non-clustered drug resistance (DR) isolates indicated that the epidemics is driven by both new DR development and acquired resistance. Conclusion: The high prevalence of drug-resistant TB due to geographically restricted sub-lineages (L4.2.2.ETH) indicates the ongoing local micro epidemics. The Mtb drug resistance surveillance system must be improved. Further evolutionary analysis of L4.2.2.ETH strain is highly desirable to understand evolutionary forces that leads L4.2.2.ETH in to high level DR and transmissible sub-lineage.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipSample collection was funded by the Institute of Biotechnology, Bahir Dar University, through the Endalkachew Nibret Mega Project. The Mtb culture and identification-related laboratory supply was supported by the Amhara Public Health Institute, Bahir Dar, Ethiopia. Whole-genome sequencing was performed with the great support of National Center of Microbiology, Institute of Carlos III, Madrid, Spain. The International Federation for Clinical Chemistry (IFCC) provided financial support to Daniel Mekonnen through the IFCC Professional Exchange Program (PEP) for three months stay in Madrid Spain for conducting the WGS analysis.es_ES
dc.format.page6859-6870es_ES
dc.format.volume16es_ES
dc.identifier.citationInfect Drug Resist. 2023 Oct 26:16:6859-6870.es_ES
dc.identifier.doi10.2147/IDR.S429001es_ES
dc.identifier.issn1178-6973es_ES
dc.identifier.journalInfection and drug resistancees_ES
dc.identifier.pubmedID37908783es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16669
dc.language.isoenges_ES
dc.publisherDove Medical Presses_ES
dc.relation.publisherversionhttps://doi.org/10.2147/IDR.S429001es_ES
dc.repisalud.centroISCIII::Centro Nacional de Medicina Tropicales_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectMycobacterium tuberculosises_ES
dc.subjectL.4.2.2es_ES
dc.subjectSIT149es_ES
dc.subjectDrug resistancees_ES
dc.subjectEthiopiaes_ES
dc.titleMycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020-2022: In-silico Whole-Genome Sequence Analysises_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication82a8967d-0949-402d-a319-43330521cad3
relation.isAuthorOfPublication0486607e-59e8-448a-9655-41a1b3082d80
relation.isAuthorOfPublicationa4ef21b9-107c-4909-83e9-ca9b48f79803
relation.isAuthorOfPublicatione8eb8cef-ea3b-4908-be79-6c38f09d8fd1
relation.isAuthorOfPublication9bbbbb77-bd32-466c-820b-44bdad635fc4
relation.isAuthorOfPublication.latestForDiscovery82a8967d-0949-402d-a319-43330521cad3

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
MycobacteriumTuberculosisSub-Lineage_2023.pdf
Size:
1.93 MB
Format:
Adobe Portable Document Format
Description: